A retrospective study of 34 patients with unicentric and multicentric Castleman's disease: Experience from a single institution

Jiang,Jin‑Peng; Shen,Xiao‑Fei; Du,Jun‑Feng; Guan,Wen‑Xian

doi:10.3892/ol.2017.7625

A retrospective study of 34 patients with unicentric and multicentric Castleman's disease: Experience from a single institution

Authors:
- Jin‑Peng Jiang
- Xiao‑Fei Shen
- Jun‑Feng Du
- Wen‑Xian Guan
View Affiliations

Affiliations: Department of Rehabilitation Medicine, General Hospital of Beijing Military Command, Beijing 100700, P.R. China, Department of General Surgery, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, P.R. China, Department of General Surgery, General Hospital of Beijing Military Command, Beijing 100700, P.R. China
Published online on: December 14, 2017 https://doi.org/10.3892/ol.2017.7625
Pages: 2407-2412

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to share the experience of a single institute in the diagnosis, use of accessory examinations and treatment strategies of Castleman's disease (CD). The present study analyzed 34 patients (13 males and 21 females) with CD who were hospitalized between January 2006 and September 2014. The patients were divided into two groups based on the anatomical distribution of the disease: Unicentric CD (UCD) and multicentric CD (MCD). Histological data was obtained from lymph node biopsies. All clinical data were acquired by reviewing patients' medical records and contacting patients by telephone. A total of 27 patients had UCD and 7 patients had MCD. All 27 patients with UCD with benign symptoms underwent complete diagnostic surgical resection and survived, with the exception of 1 patient who succumbed to pancreatic head carcinoma 13 months after surgery. A total of 7 patients with MCD presented with systemic symptoms and 2 of these patients declined treatment following the definite diagnosis of CD. The remaining 5 patients were treated with various strategies, including surgical resection and further glucocorticoid treatment, intravenous siltuximab, rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy or hematopoietic stem cell transplantation. A total of 3 patients with MCD survived, with a median follow‑up period of 69 months. The present study indicates that complete surgical resection is currently the standard treatment for UCD. Perioperative use of multidetector computed tomography and the laparoscopic approach have certain advantages in UCD. Molecular target therapy is effective in patients with stable MCD, and hematopoietic stem cell transplantation may be beneficial in certain patients with MCD and disease progression.

View Figures

View References

1	Castleman B and Towne VW: Case records of the Massachusetts general hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N Engl J Med. 251:396–400. 1954.PubMed/NCBI
2	El-Osta HE and Kurzrock R: Castleman's disease: From basic mechanisms to molecular therapeutics. Oncologist. 16:497–511. 2011. View Article : Google Scholar : PubMed/NCBI
3	Waterston A and Bower M: Fifty years of multicentric Castleman's disease. Acta Oncol. 43:698–704. 2004. View Article : Google Scholar : PubMed/NCBI
4	Keller AR, Hochholzer L and Castleman B: Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 29:670–683. 1972. View Article : Google Scholar : PubMed/NCBI
5	Casper C: The aetiology and management of Castleman disease at 50 years: Translating pathophysiology to patient care. Br J Haematol. 129:3–17. 2005. View Article : Google Scholar : PubMed/NCBI
6	Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, Nakahata T, Kawai H, Tagoh H, Komori T, et al: Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 74:1360–1367. 1989.PubMed/NCBI
7	Vinzio S, Ciarloni L, Schlienger JL, Rohr S, Méchine A and Goichot B: Isolated microcytic anemia disclosing a unicentric Castleman disease: The interleukin-6/hepcidin pathway? Eur J Intern Med. 19:367–369. 2008. View Article : Google Scholar : PubMed/NCBI
8	Reddy D and Mitsuyasu R: HIV-associated multicentric Castleman disease. Curr Opin Oncol. 23:475–481. 2011. View Article : Google Scholar : PubMed/NCBI
9	Shen XF, Guan WX, Cao K, Wang H and Du JF: Small bowel volvulus with jejunal diverticulum: Primary or secondary? World J Gastroenterol. 21:10480–10484. 2015. View Article : Google Scholar : PubMed/NCBI
10	Dispenzieri A: Castleman disease. Cancer Treat Res. 142:293–330. 2008.PubMed/NCBI
11	Műzes G, Sipos F, Csomor J and Sréter L: Multicentric Castleman's disease: A challenging diagnosis. Pathol Oncol Res. 19:345–351. 2013. View Article : Google Scholar : PubMed/NCBI
12	Herrada J, Cabanillas F, Rice L, Manning J and Pugh W: The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med. 128:657–662. 1998. View Article : Google Scholar : PubMed/NCBI
13	Bonekamp D, Horton KM, Hruban RH and Fishman EK: Castleman disease: The great mimic. Radiographics. 31:1793–1807. 2011. View Article : Google Scholar : PubMed/NCBI
14	Frizzera G: Castleman's disease and related disorders. Semin Diagn Pathol. 5:346–364. 1988.PubMed/NCBI
15	Talat N, Belgaumkar AP and Schulte KM: Surgery in Castleman's disease: A systematic review of 404 published cases. Ann Surg. 255:677–684. 2012. View Article : Google Scholar : PubMed/NCBI
16	Barker R, Kazmi F, Stebbing J, Ngan S, Chinn R, Nelson M, O'Doherty M and Bower M: FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease. Eur J Nucl Med Mol Imaging. 36:648–652. 2009. View Article : Google Scholar : PubMed/NCBI
17	Ye B, Gao SG, Li W, Yang LH, Zhao SH, Ma K, Zhu XL, Liu XY and Sun KL: A retrospective study of unicentric and multicentric Castleman's disease: A report of 52 patients. Med Oncol. 27:1171–1178. 2010. View Article : Google Scholar : PubMed/NCBI
18	Meador TL and McLarney JK: CT features of Castleman disease of the abdomen and pelvis. AJR Am J Roentgenol. 175:115–118. 2000. View Article : Google Scholar : PubMed/NCBI
19	Mangini M, Aiani L, Bertolotti E, Imperatori A, Rotolo N, Paddeu A, Uccella S, Carrafiello G and Fugazzola C: Parapancreatic Castleman disease: Contrast-enhanced sonography and CT features. J Clin Ultrasound. 35:207–211. 2007. View Article : Google Scholar : PubMed/NCBI
20	Noh OK, Lee SW, Lee JW, Kim SY, Kim CS, Choi EK, Kim JH and Ahn SD: Cases report of unicentric Castleman's disease: Revisit of radiotherapy role. Radiat Oncol J. 31:48–54. 2013. View Article : Google Scholar : PubMed/NCBI
21	Frizzera G, Banks PM, Massarelli G and Rosai J: A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients. Am J Surg Pathol. 7:211–231. 1983. View Article : Google Scholar : PubMed/NCBI
22	Lee HJ, Jeon HJ, Park SG and Park CY: Castleman's disease of the spleen. World J Gastroenterol. 21:1675–1679. 2015. View Article : Google Scholar : PubMed/NCBI
23	Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME and Brennan MF: The management of unicentric and multicentric Castleman's disease: A report of 16 cases and a review of the literature. Cancer. 85:706–717. 1999. View Article : Google Scholar : PubMed/NCBI
24	Soumerai JD, Sohani AR and Abramson JS: Diagnosis and management of Castleman disease. Cancer Control. 21:266–278. 2014. View Article : Google Scholar : PubMed/NCBI
25	Weisenburger DD, Nathwani BN, Winberg CD and Rappaport H: Multicentric angiofollicular lymph node hyperplasia: A clinicopathologic study of 16 cases. Hum Pathol. 16:162–172. 1985. View Article : Google Scholar : PubMed/NCBI
26	van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B and Kurzrock R: A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease. Oncotarget. 6:30408–30419. 2015. View Article : Google Scholar : PubMed/NCBI